The head of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, said that the Ministry of Health would soon allow clinical trials of a drug for COVID-19 based on monoclonal antibodies. He told RIA Novosti about this.
According to him, the center has already submitted all the necessary documents to the ministry, and permission should be received in the near future.
Earlier, Gunzburg announced the start of clinical trials of a drug against coronavirus based on monoclonal antibodies.
He said that the trials would take from three to four months, and it would be possible to release the drug in the second half of spring. “But the fact that this drug is effective is already known from Western analogues,” Gunzburg said.
Research on a monoclonal antibody cocktail for the treatment of COVID-19 began in January and is expected to be completed in 2-3 months. The scientist said the drug would have to effectively neutralize the virus.
The drug Fluorthiazinon, which will be used as a prophylaxis for severe bacterial complications in those infected, is already in the second stage of clinical trials, Gunzburg concluded.
bbabo.Net